NR3C2 and atrial fibrillation: Preclinical models as well as clinical trials have largely established the beneficial effects of finerenone, with this novel non-steroidal MR antagonist improving cardiac remodeling, reducing the risk of atrial fibrillation, decreasing the UACR, improving mitochondrial dysfunction and regulating metabolism.